| Literature DB >> 27506613 |
Tebelay Dilnessa1, Adane Bitew2.
Abstract
BACKGROUND: Staphylococcus aureus particularly MRSA strains are one of the major causes of community and hospital acquired bacterial infections. They are also becoming increasingly multi-drug resistant and have recently developed resistance to vancomycin, which has been used successfully to treat MRSA for many years. In-vitro determination of drug resistance patterns of S. aureus is critical for the selection of effective drugs for the treatment of staphylococci infections. The main aim of this study was to determine the prevalence of methicillin resistant S. aureus strains from different clinical specimens from patients referred for routine culture and sensitivity testing.Entities:
Keywords: Beta-lactamase; MRSA; MSSA; Penicillin binding protein; Prevalence
Mesh:
Substances:
Year: 2016 PMID: 27506613 PMCID: PMC4977752 DOI: 10.1186/s12879-016-1742-5
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Association of S. aureus in study participants with regard to gender and age group at Yekatit 12 Hospital Medical College from September 2013 to April 2014, Addis Ababa, Ethiopia
| Variable | Presence of | COR(95 % CI) |
| AOR(95 % CI) |
| ||
|---|---|---|---|---|---|---|---|
| Yes (N/%) | No (N/%) | ||||||
| Sex | Male | 106(16.2) | 548(83.8) | 0.73(0.54, 0.99) | 0.049 | 1.05(0.72,1.53) | 0.771 |
| Female | 88(12.5) | 618(87.5) | 1 | - | 1 | - | |
| Age group | <1 | 9(8.6) | 96(91.4) | 1.47(0.55, 3.92) | 0.434 | - | - |
| 1–14 | 48(10.4) | 413(89.6) | 1.19(0.55, 2.54) | 0.651 | - | - | |
| 15–24 | 46(21.0) | 164(79.0) | 0.49(0.23, 1.06) | 0.072 | - | - | |
| 25–34 | 38(17.0) | 184(83.0) | 0.67(0.31, 1.46) | 0.315 | - | - | |
| 35–44 | 26(16.8) | 129(83.2) | 0.68(0.30, 1.55) | 0.366 | - | - | |
| 45–64 | 18(13.6) | 115(86.4) | 0.88(0.37, 2.08) | 0.779 | - | - | |
| > = 65 | 9(12.2) | 65(87.8) | 1 | - | - | - | |
COR crude odds ratio, AOR adjusted odds ratio, CI Confidence interval
Isolation rate of S. aureus from clinical specimens at Yekatit 12 Hospital Medical College from September 2013 to April 2014, Addis Ababa, Ethiopia
| Specimen type | Presence of | Total | AOR | 95 % CI |
| |
|---|---|---|---|---|---|---|
| Yes (N/%) | No (N/ %) | Na | ||||
| Pus/abscess | 118(55.4) | 95(44.6) | 213 | 67.074 | (9.11, 493.8) | 0.001** |
| Nasal swab | 9(33.3) | 18(66.7) | 27 | 27.000 | (3.19, 228.05) | 0.002** |
| Throat swab | 7(17.0) | 34(83.0) | 41 | 11.118 | (1.31, 94.37) | 0.027* |
| Vaginal discharge | 3(2.5) | 118(97.5) | 121 | 1.373 | (0.14, 13.50) | 0.786 |
| Urine | 6(2.8) | 211(97.2) | 217 | 1.536 | (0.18, 13.02) | 0.694 |
| Eye swab | 2(12.5) | 14(87.5) | 16 | 7.714 | (0.65, 91.32) | 0.105 |
| Blood | 17(7.6) | 206(92.4) | 223 | 4.456 | (0.58, 34.23) | 0.151 |
| Body fluids | 4(5.3) | 71(94.7) | 75 | 3.042 | (0.33, 28.0) | 0.326 |
| Stool | 3(1.8) | 168(98.2) | 171 | 0.964 | (0.09, 9.46) | 0.975 |
| Ear discharge | 24(28.2) | 61(71.8) | 85 | 21.246 | (2.78, 162.3) | 0.003** |
| Sputum | 1(0.8) | 54 (98.2) | 55 | 1 | - | - |
AOR adjusted odds ratio
a Total sample
** Significant at P value < 0.01, * Significant at P value < 0.05
Fig. 1Methicillin susceptibility pattern of S. aureus from participants at Yekatit 12 Hospital Medical College from September 2013 to April 2014, Addis Ababa, Ethiopia
Association of methicillin resistant pattern of S. aureus in study participants with gender and age group at Yekatit 12 Hospital Medical College from September 2013 to April 2014, Addis Ababa, Ethiopia
| Variable | MRSA | MSSA |
| COR | 95 % CI |
| |
|---|---|---|---|---|---|---|---|
| N (%) | N (%) | N | |||||
| Sex | Male | 19(19.9) | 87(82.1) | 106 | 0.94 | (0.44, 1.98) | 0.873 |
| Female | 15(17.0) | 73(83.0) | 88 | 1 | - | - | |
| Age group | <1 | 0(0) | 9(100) | 9 | 0.00 | - | 0.999 |
| 1–14 | 7(14.6) | 41(85.4) | 48 | 1.67 | (0.29, 9.76) | 0.567 | |
| 15–24 | 8(17.4) | 38(82.6) | 46 | 1.36 | (0.24, 7.78) | 0.732 | |
| 25–34 | 4(10.5) | 34(89.5) | 38 | 2.43 | (0.37, 15.95) | 0.356 | |
| 35–44 | 8(30.8) | 18(69.2) | 26 | 0.64 | (0.11, 3.80) | 0.626 | |
| 45–64 | 5(27.8) | 13(72.2) | 18 | 0.74 | (0.11, 4.86) | 0.757 | |
| > = 65 | 2(22.2) | 7(77.8) | 9 | 1 | - | - | |
COR crude odds ratio
Association of methicillin resistant S. aureus to different clinical specimens at Yekatit 12 Hospital Medical College from September 2013 to April 2014, Addis Ababa, Ethiopia
| Type of specimen | MRSA | MSSA | Total | COR | 95 % CI |
|
|---|---|---|---|---|---|---|
| N (%) | N (%) | Na | ||||
| Pus/abscess | 24(20.3) | 94(79.7) | 118 | 0.511 | (0.11, 2.19) | 0.366 |
| Nasal swab | 3(33.3) | 6(66.7) | 9 | 0.638 | (0.11, 3.49) | 0.605 |
| Throat swab | 2(28.6) | 5(71.4) | 7 | 0.000 | - | 0.999 |
| Vaginal discharge | 0(0) | 3(100) | 3 | 0.000 | - | 0.999 |
| Urine | 0(0) | 6(100) | 6 | 1.915 | (0.41, 8.95) | 0.409 |
| Eye swab | 0(0) | 2(100) | 2 | 0.000 | - | 0.999 |
| Blood | 2(11.8) | 15(88.2) | 17 | 0.000 | - | 0.999 |
| Body fluids | 0(0) | 4(100) | 4 | 0.000 | - | 0.999 |
| Stool | 0(0) | 3(100) | 3 | 0.000 | - | 1.000 |
| Ear discharge | 3(12.5) | 21(87.5) | 24 | 1.787 | (0.49, 6.49) | 0.378 |
| Sputum | 0(0) | 1(100) | 1 | 1 | - | - |
COR crude odds ratio
a total S. aureus isolates from each type of sample
Antimicrobial susceptibility pattern of S. aureus strains to different antimicrobial agents at Yekatit 12 Hospital Medical College from September 2013 to April 2014, Addis Ababa, Ethiopia
| Antibiotics | Resistant | Susceptible |
|---|---|---|
| N (%) | N (%) | |
| Cefoxitin [30 μg] | 34(17.5) | 160(82.5) |
| Amoxicillin-clavulanate [30 μg] | 36(18.5) | 158(81.5) |
| Penicillin G [10 U] | 187(96.4) | 7(3.6) |
| Vancomycina | 10(5.1) | 184(94.9) |
| SXT [1.25/23.75 μg] | 103(53.1) | 91(46.9) |
| Chloramphenicol [30 μg] | 36(18.6) | 158(81.4) |
| Gentamycin [10 μg] | 26(13.4) | 168(86.6) |
| Cefuroxime [30 μg] | 40(20.6) | 154(79.4) |
| Clindamycin [30 μg] | 23(11.9) | 171(88.1) |
| Ciprofloxacin [5 μg] | 61(31.4) | 133(68.6) |
| Cephalothin [10 μg] | 37(19.1) | 157(80.9) |
| Erythromycin [15 μg] | 103(53.1) | 91(46.9) |
SXT Trimethoprim-Sulfamethoxazole
a concentration from 2 μg/ml to16μg/ml
Association of methicillin resistant and sensitive S. aureus to different antimicrobial classes at Yekatit 12 Hospital Medical College from September 2013 to April 2014, Addis Ababa, Ethiopia
| Antibiotics | MRSA ( | MSSA ( | AOR | 95 % CI |
|
|---|---|---|---|---|---|
| N (%) | N (%) | ||||
| AMC [30 μg] | 34(100) | 2(1.3) | 9.809 | (1.56, 61.69) | 0.015* |
| Penicillin G [10 U] | 34(100) | 153(95.6) | 0.000 | - | 0.99 |
| Vancomycina | 10(29.4) | 0(0) | 0.000 | - | 0.99 |
| SXT [1.25/23.75 μg] | 34(100) | 69(43.1) | 16.24 | (0.41, 63.28) | 0.135 |
| Chloramphenicol [30 μg] | 16(47) | 20(12.5) | 1.130 | (0.09, 13.63) | 0.923 |
| Gentamycin [10 μg] | 13(38.2) | 13(8.1) | 0.896 | (0.07, 10.98) | 0.931 |
| Cefuroxime [30 μg] | 34(100) | 6(3.8) | 216.17 | (10.8, 432.2) | 0.001** |
| Clindamycin [30 μg] | 18(53) | 5(3.1) | 13.22 | (1.99, 87.62) | 0.007** |
| Ciprofloxacin [5 μg] | 28(82.5) | 33(20.6) | 0.615 | (0.10, 3.73) | 0.598 |
| Erythromycin [15 μg] | 34(100) | 69(43.1) | 9.044 | (0.49, 16.05) | 0.136 |
| Cephalothin [10 μg] | 34(100) | 3(1.8) | 1 | - | - |
AMC Amoxilin- clavulanic acid, SXT Trimethoprim-Sulfamethoxazole
a concentration from 2 μg/ml to16μg/ml
** Significant at P value < 0.01, * Significant at P value < 0.05
Multi-drug resistance nature of S. aureus isolates at Yekatit 12 Hospital Medical College from September 2013 to April 2014, Addis Ababa, Ethiopia
| Antibiotics | Resistant strains | |
|---|---|---|
| N | % | |
| P, E, SXT | 18 | 18.40 |
| P, G, E | 5 | 5.10 |
| P, C, SXT | 4 | 4.08 |
| P, C, CIP | 3 | 3.06 |
| P, CIP, E, SXT | 13 | 13.26 |
| P, G, C, E | 3 | 3.06 |
| P, G, C, SXT | 2 | 2.04 |
| P, CIP, E, SXT | 1 | 1.02 |
| P, AMC, E, SXT | 1 | 1.02 |
| P, FOX, G, SXT | 1 | 1.02 |
| P, FOX, E, SXT | 2 | 2.04 |
| P, C, CIP, E, SXT | 2 | 2.04 |
| P, G, CIP, AMC, SXT | 1 | 1.02 |
| P, G, CIP, E, SXT | 1 | 1.02 |
| P, G, C, E, SXT | 1 | 1.02 |
| P, CIP, E, SXT, DA | 2 | 2.04 |
| P, FOX, C, E, SXT | 1 | 1.02 |
| P, G, C, CIP, CXM, SXT | 1 | 1.02 |
| P, G, C, CIP, E, SXT | 3 | 3.06 |
| P, G, C, AMC, E, SXT | 1 | 1.02 |
| P, FOX, CIP, E, SXT, DA | 3 | 3.06 |
| P, FOX, C, E, CXM, SXT | 2 | 2.04 |
| P, G, C, CIP, E, SXT, DA | 2 | 2.04 |
| P, FOX, G, C, CIP, E, SXT | 2 | 2.04 |
| P, FOX, C, CIP, E, CXM, SXT | 5 | 5.10 |
| P, FOX, C, E, CXM, SXT, DA | 1 | 1.02 |
| P, FOX, CIP, AMC, KF, E, CXM | 2 | 2.04 |
| P, FOX, CIP, AMC, KF, SXT, DA | 2 | 2.04 |
| P, FOX, G, C, CIP, E, CXM, SXT | 2 | 2.04 |
| P, FOX, VAN, CIP,AMC, E, SXT, DA | 5 | 5.10 |
| P, FOX, VAN, CIP, AMC, E, CXM, SXT, DA | 1 | 1.02 |
| P, FOX, C, CIP, AMC, E, CXM, SXT, DA | 1 | 1.02 |
| P, FOX, VAN, CIP, AMC, KF, E, SXT, DA | 1 | 1.02 |
| P, FOX, VAN, G, C, CIP, AMC, E, SXT, DA | 1 | 1.02 |
| P, FOX, VAN, G, C, CIP, AMC, E, CXM, SXT, DA | 2 | 2.04 |
| Total | 98 | 100.00 |
P Penicillin G, CIP Ciprofloxacin, AMC Amoxicillin-clavulanic acid, C Chloramphenicol, FOX Cefoxitin, KF Cephalothin, E Erythromycin, G Gentamycin, VAN Vancomycin, SXT Trimethoprim-sulphamethoxazole, DA Clindamycin, CXM Cefuroxime